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Abstract
Purpose—Little is known about different ways of assessing risk of distant recurrence following 
cancer treatment (e.g., numeric or descriptive). We sought to evaluate the association between 
overestimation of risk of distant recurrence of breast cancer and key patient reported outcomes, 
including quality of life and worry.
Methods—We surveyed a weighted random sample of newly diagnosed patients with early-stage 
breast cancer identified through SEER registries of Los Angeles & Georgia (2013-14) ∼2 months 
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after surgery (N=2578, RR=71%). Actual 10-year risk of distant recurrence after treatment was 
based on clinical factors for women with DCIS & low risk invasive cancer (Stg 1A, ER+HER2-, 
Gr 1-2). Women reported perceptions of their risk numerically (0 – 100%), with values ≥10% for 
DCIS & ≥20% for invasive considered overestimates. Perceptions of “moderate, high or very 
high” risk were considered descriptive overestimates. In our analytic sample (N=927), we assessed 
factors correlated with both types of overestimation and report multivariable associations between 
overestimation and QoL (PROMIS physical & mental health) and frequent worry.
Results—30.4% of women substantially overestimated their risk of distant recurrence 
numerically and 14.7% descriptively. Few factors other than family history were significantly 
associated with either type of overestimation. Both types of overestimation were significantly 
associated with frequent worry, and lower QoL.
Conclusions—Ensuring understanding of systemic recurrence risk, particularly among patients 
with favorable prognosis, is important. Better risk communication by clinicians may translate to 
better risk comprehension among patients and to improvements in QoL.
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Introduction
The long-term prognosis for women with a new diagnosis of ductal carcinoma in situ (DCIS, 
or stage 0) or early stage invasive breast cancer with favorable biology is generally excellent.
[1,2] Studies have shown that initial management translates into a high likelihood of cure.[2] 
Only a small proportion of patients experience systemic recurrence of their cancer, which 
can lead to mortality from the disease. The likelihood of systemic recurrence after treatment 
for women with node negative, estrogen receptor positive (ER) invasive breast cancer and 
favorable tumor biology 5 year metastases free survival rates is less than 2%; for those with 
DCIS, there is almost no chance of systemic recurrence.[2-4] Yet, understanding and 
interpreting risk, is challenging, and studies have found that many women with breast cancer 
significantly overestimate their risk of distant recurrence after treatment.[5-8]
Importantly, overestimation of perceived risk of recurrence and associated fear of 
recurrence, may negatively contribute to long-term outcomes that are important for cancer 
survivors, such as quality of life (QoL) and ongoing worry. It may also motivate patients to 
prefer more extensive treatment and follow up care.[9,10] Prior work has identified an 
important link between overestimation of risk and lower scores on physical health 
assessments (5) and on fear of recurrence after treatment.7 It may also motivate patients to 
prefer more extensive treatment and follow up care.[9,10]
Furthermore, despite a rich literature in risk communication documenting different types of 
risk measurement, no studies have explicitly assessed whether it matters more if patients 
have an accurate numeric understanding of their risk or a more general descriptive 
comprehension (i.e. “gist”[11]) of their own risk of cancer spreading. While previous studies 
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lend an important perspective on this issue from clinical samples, there have not been large 
population-based studies among racially/ethnically diverse samples on this issue.
Our study had two objectives. First, to evaluate correlates of overestimation of distant 
recurrence, measured both numerically and descriptively, in a diverse, contemporary, 
population-based sample of breast cancer patients with DCIS and early stage invasive breast 
cancer. Second, to determine the association between overestimation of risk using two 




The iCanCare Study, a large, diverse, population-based survey study of women with 
favorable prognosis breast cancer, accrued women ages 20-79 with newly diagnosed breast 
cancer (DCIS and stages I-II) as identified by rapid reporting systems from the Surveillance 
Epidemiology and End Results (SEER) registries of Georgia and Los Angeles County in 
2013-2014. Black, Asian, and Hispanic women were oversampled in Los Angeles.[12] We 
selected 3,880 of whom 249 women were later deemed ineligible due to having a prior 
cancer diagnosis or stage III or IV disease; residing outside the SEER registry area; being 
deceased, too ill or unable to complete a survey in Spanish or English. Of 3,631 eligible 
women remaining, 1,053 did not return mailed surveys, refused to participate or were lost to 
follow up. Non-respondents did not differ significantly from respondents on key variables, 
including stage and race/ethnicity. Of 2,578 patients who responded (71%), for this analysis 
the following exclusions were made: 1388 because their actual risk of recurrence was higher 
than that for DCIS or our low risk invasive cases, 165 because they did not have sufficient 
data to calculate actual risk, and 98 because they had bilateral disease. The resulting analytic 
sample was 927 women.
Data Collection
Patients were sent surveys approximately 2 months after surgery. We provided a $20 cash 
incentive and used a modified Dillman method for patient recruitment, as done in prior 
work.[12,13] All materials were sent in English and Spanish to those with Spanish 
surnames.[12] Survey responses were then merged with clinical data from SEER. The study 
was approved by the Institutional Review Boards of the University of Michigan, University 
of Southern California and Emory University and the Committee for the Protection of 
Human Subjects and the California Cancer Registry.
Questionnaire Design and Content
Patient questionnaire content was guided by a conceptual framework, research questions, 
and hypotheses. We chose established measures when available and developed new 
measures, when necessary, drawing from the literature and our prior research.[14-16] We 
used standard techniques to assess content validity, including review by survey design 
experts, cognitive pre-testing with patients, and pilot studies in selected clinic populations.
Hawley et al. Page 3














Actual Risk of Distant Recurrence—We first created our analytic sample with highly 
favorable prognosis, and thus very low actual risk of distant recurrence, using stage, 
histology and biology. Using SEER data, women were classified as having DCIS (stage 0) 
(with almost no risk of distant recurrence) or low risk invasive breast cancer (with <10% 
actual risk of distant recurrence); stage 1A, ER+, HER2-, tumor grade 1-2, and either having 
a 21-gene assay test result of 0-10, or the result was not indicated.[2,3] Actual risk was 
assessed following treatment (surgery, radiation, chemotherapy).
Overestimation of Risk of Distant Recurrence
We assessed overestimation by using both a numeric and descriptive method. In the survey, 
women were asked “After receiving all the planned treatments, what do you think is the 
chance that your cancer will spread to other parts of your body in 10 years?” and asked (1) 
to provide a numeric estimate on a scale from 0 to 100% and (2) to choose a descriptive risk 
category (very low, low, moderate, high, very high). For women with DCIS, we considered 
them to have overestimated risk numerically if they perceived a chance of distant recurrence 
of 10% or higher; for women with invasive cancer, overestimation was considered 20% or 
higher. These percent cutoffs were chosen by clinical experts to represent “substantial 
overestimation of risk of recurrence” as they are more than twice/double the percent of 
“actual risk of systemic recurrence” expected following treatment for these patients with 
highly favorable prognosis.[2,3] For all women, if they indicated that their systemic risk of 
recurrence was moderate, high or very high we considered them to have overestimated their 
risk descriptively.
To understand the independent and combined effects of numeric and descriptive discordant 
risk perception, we additionally combined the two risk measures into one 4-level categorical 
risk summary measure: (1) correct on both numeric and descriptive measure (N+, D+), (2) 
correct on numeric but overestimated descriptive (N+, D-), (3) correct on descriptive and 
overestimated on numeric (N-, D+), and (4) overestimated on both numeric and descriptive 
measures (N-, D-).
Quality of Life
Quality of life (QoL) was measured with the Patient Reported Outcomes Measurement 
Information System (PROMIS) measure, providing Global Mental Health (GMH) and 
Global Physical Health (GPH) subscales. The PROMIS scales are validated QoL measures 
that have been widely used to assess patient reported QoL in cancer.[17,18] The 10-item 
scale is scored and standardized into the GMH and GPH. PROMIS scores are normalized to 
a mean of 50 with a standard deviation of 10. A score of < 40 is considered a clinically 
meaningful decline/reduction in QoL. Following this scoring recommendation, for our 
analysis, scores of ≤ 40 for GPH and GMH were used to indicate low (worse) mental and 
physical health.[17]
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Frequent Worry about Recurrence
We asked women to indicate on a 5-point scale how often they worried about the cancer 
coming back in the past month (not at all, a little, sometimes, a lot, almost always). For these 
analyses, those who indicated they worried at least sometimes were considered to have 
frequent worry.
Covariates
Covariates used in this analysis included patient demographics and clinical factors. We 
included age, race/ethnicity (White, Black, Latina, Asian, Other/Unknown), educational 
attainment (high school graduate or less, some college or more), marital status (married/
partnered vs. not), employment (employed; retired; unemployed), number of comorbid 
health conditions (none vs. 1 or more), and family history of breast cancer (none vs. 1 or 
more first degree relatives). Breast cancer treatment, including surgical treatment type 
(lumpectomy; unilateral mastectomy; bilateral mastectomy) and receipt of chemotherapy 
(yes/no), was also collected via survey. We controlled for patient factors that could confound 
QoL and worry by including patient report of being bothered by treatment side effects 
(yes/no) at the time of the survey and a measure of decisional anxiety. We further controlled 
for treatment (surgery type, radiation and chemotherapy receipt).
Statistical Analyses
We first calculated the proportion of women who overestimated their risk of distant 
recurrence using both the numeric and descriptive measures, as a whole and separately for 
women with DCIS and invasive cancer. Multivariable, weighted logistic regression was used 
to explore correlates of overestimation and to estimate the association between 
overestimation using both numeric and descriptive forms and each PROMIS measure 
(physical and mental health) and frequency of worry, after adjustment for all covariates 
above. We further assessed the association between the combined overestimation measure 
and QoL. Survey and SEER item non-response was low (<5%) for all covariates; however, 
to correct for the potential of bias due to missing data, values for missing items were 
imputed using sequential regression multiple imputation (SRMI).[19] Five multiply imputed 
datasets were analyzed and model estimates were combined to account for additional 
uncertainty due to imputation. Results were compared between SRMI analyses and 
complete-case analyses for any meaningful differences. Odds ratios (OR) with 95% 
confidence intervals (CI) are reported for models, with p-values ≤0.05 considered 
significant. All statistical analyses incorporated weights to account for differential 
probabilities of sample selection and non-response. All analyses were performed using SAS 
version 9.4 (Cary, NC).
Results
Patient Characteristics—The characteristics of the analytic sample (N=927) are 
provided in Table 1. The mean age of patients was 63 (range: 31-82). The diversity of the 
sample reflected the population-based sampling approach: 57.7% white, 17.7% black, 14.4% 
Latina, 7.5% Asian and 2.7% other. Most reported being married (61.4%) and having some 
college or more education (71.6%). About two-thirds of patients were treated with 
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lumpectomy (68.3%), and a minority (3.6%) reported having received chemotherapy at the 
time of the survey.
Overall, 30.4% of women with highly favorable prognosis substantially overestimated their 
risk of distant recurrence numerically, 14.7% descriptively, and 12.1% overestimated using 
both definitions. Among women with DCIS, 35.1% overestimated numerically, and 13.1% 
descriptively, while 24.3% of women with invasive cancer overestimated numerically and 
16.7% descriptively (Fig.1a).
About 10% of patients reported poor mental health and 18.2% poor physical health using 
PROMIS measures. About a third (30.8%) of women indicated that they worried about the 
cancer coming back “at least sometimes.” (Fig. 1b).
Few demographic or clinical factors were consistently associated with overestimating risk 
both numerically and descriptively. Black (vs. white) patients were less likely to 
overestimate numerically (OR: 0.47; 95% CI 0.29-0.76) but not descriptively. Those with 
more education more often overestimated numerically (OR: 1.46; 95% CI 1.02-2.09). 
Women with a family history of breast cancer were more likely to overestimate both 
numerically (OR: 1.45; 95% CI 1.03-2.04) and descriptively (OR: 1.79; 95% CI 1.18-2.69). 
Finally, women who received bilateral mastectomy (vs. breast conservation) were 
significantly less likely to overestimate their risk of recurrence numerically (OR: 0.46; 95% 
CI 0.28-0.76). (Data not shown).
Controlling for all covariates, patients who overestimated their risk numerically had higher 
odds of reporting frequent worry (OR 2.87; 95% CI 1.90-4.33) than those who did not 
overestimate. These women were also more likely to report poor physical health (OR: 1.90; 
95% CI 1.11-3.26). Women who overestimated their risk descriptively more often reported 
frequent worry (OR: 3.16; 95% CI 1.87-5.35) and lower mental health (OR: 2.52; 95% CI 
1.24-5.08), but were no more likely to report worse physical health. The covariates 
significantly (p<0.05) associated with poor physical health, poor mental health and more 
frequent worry are included in Table 2.
The point estimates and 95% confidence intervals for the association between the 4-category 
risk perception measure described above and frequent worry are presented in Fig 2. As is 
apparent from the figure, in adjusted analysis, there is a nearly linear association between 
risk perception and frequent worry. Compared to women who correctly reported both 
numeric and descriptive risk (N+, D+), N-, D+ women were 3.2 times as likely to have 
frequent worry, N+, D- women were 6.2 times as likely, and those who overestimated on 
both measures (N-, D-) were 8.4 times as likely to have frequent worry.
Discussion
In this large, diverse, population-based sample of newly diagnosed and treated breast cancer 
patients with favorable prognosis, we found that nearly a third (30.4%) overestimated the 
numeric risk of systemic recurrence to be more than twice their actual risk. A unique finding 
relative to prior work was that numeric overestimation was more common than descriptive 
or “gist” overestimation (14.7%). Particularly striking was that almost a third of women with 
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DCIS, who have almost no chance of systemic recurrence, believed their risk to be at 10% or 
higher.
This study confirms prior research showing that many women diagnosed with breast cancer, 
including DCIS, do not have an accurate understanding of the likelihood of their cancer 
spreading systemically.[5-8] However, our study substantially extends this literature to a 
diverse, population-based sample and by assessing patients' understanding of two different 
measures of risk perception; a numeric (number-based) and a descriptive (word-based) 
measure. While we did not find a consistent set of demographic or clinical factors associated 
with a tendency to overestimate risk using either measure, one factor, having a family 
history of breast cancer, was associated with both types of overestimation. We conclude that 
no assumptions should be made about the ability of patients to comprehend their risk, but 
that patient understanding of their familiar risk may contribute to their assessment of their 
own risk. Our findings reflect the difficulty of communicating complex risk information 
(e.g., distant metastatic recurrence versus new primary) in a situation that is emotionally 
charged and affectively driven.[20]
Our study revealed associations between overestimation and reduced physical and mental 
health, using validated PROMIS QoL measures, and more frequent patient self-reported 
worry about recurrence. Our results are consistent with other work showing an association 
between overestimation and reduced physical health.[5] However, our study further suggests 
that how overestimation is expressed may influence outcomes. For example, while we found 
that numeric overestimation was more common, descriptive overestimation had an 
independent influence on outcomes. While others have found that providing numbers is 
important for risk comprehension,[21] our study suggests that having a “gist” understanding 
is also very important. As a whole, these results underscore the need to ensure that women 
accurately understand their risk of systemic recurrence following treatment, in a general 
way, as well as numerically.
Importantly, our analysis included a unique assessment of patient report of their personality 
as it relates to “general anxiety” when making decisions (not specific to breast cancer 
treatment). This trait was significantly and independently associated with QoL and frequent 
worry, supporting the concept that patients who are more naturally anxious may also be 
more likely to overestimate recurrence risk and worry. These findings suggest that ideally 
patient provider communication would include the assessment and management of 
underlying anxiety related to decisions as well as communication of risk information using 
gist and numeric approaches. It is important to note that even when controlling for 
decisional anxiety, overestimation remained independently associated with frequent worry.
Little is known about underlying reasons why women have difficulty understanding this 
recurrence risk. In prior work by our team, over 80% of surgeons and oncologists reported 
that they do discuss risk of recurrence with breast cancer patients – most often using 
descriptive terms.[22] The current study suggests that despite prior clinician reports, not all 
patients comprehend risk of recurrence. Several factors may contribute, including low 
patient numeracy, or clinicians more focused on discussing risk among patients presenting 
with higher recurrence risk. Importantly, prior work also showed that despite discussing risk, 
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many oncologists and surgeons reported lack of confidence in identifying women who are 
frequent worriers and in managing worry about recurrence with their patients.[23] Our 
results suggest that clinicians should consider both as important avenues for intervention. 
Efforts to educate providers about how to effectively convey risk information to their 
patients using principles of patient centered communication across patients of diverse 
backgrounds and literacy levels are needed.[24,25] In fact, research suggests effective 
communication of uncertainty, including risk information, translates into higher decision 
satisfaction on the part of patients.[26] Effective patient-provider communication around 
risk of recurrence would benefit from further studies examining the dimensions of the 
communication process most closely aligned with patient understanding.
Strengths of this study include a large, diverse sample, clinical information to determine 
actual recurrence risk, a high participation rate, and use of weighting and multiple 
imputation methodology. However, the study has some limitations. Patients lived in two 
geographic regions, so may not represent all U.S. breast cancer patients. Although we had 
detailed clinical information from SEER to determine actual risk, it is possible that patients 
perceived additional factors influencing their risk that were not assessed. Finally, 
associations observed in the study are not necessarily causal.
Implications
Our results suggest strategies to improve patient experiences and outcomes. First, in addition 
to providing numbers, clinicians could focus attention on describing risk in general verbal 
terms as well as in numeric terms; doing both may prove easier than conveying specific 
numeric risk estimates particularly to patients with lower numeracy skills. Second, assessing 
anxiety and worry across the care trajectory, from diagnosis through the survivorship period, 
may help identify women who would benefit from support services to manage worry. There 
is a clear need to improve approaches to conveying risk information to patients as well as 
assess and manage patient anxiety about the cancer diagnosis and its treatment. Areas for 
intervention include clinician skill-building in risk communication and patient decision tools 
that present risk information in comprehensible ways practice. These types of interventions 
are needed to improve risk comprehension among patients and, if effective, may translate 
into better quality of life for patients with breast cancer.
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Fig. 1a. Overestimation of Risk of Distant Recurrence (Numeric, Descriptive, and Both) in 
Women with Favorable Prognosis Breast Cancer (Weighted)†
†The denominator population is those answering the risk perception questions. Description: 
Describes the proportion of patients who overestimated using descriptive, numeric and both 
types of measurement of risk in the population.
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Fig. 1b. Distribution of Low General Mental Health (GMH), General Physical Health (GPH), 
and Frequent Worry about Recurrence in Women with Favorable Prognosis Breast Cancer 
(Weighted)†
†The denominator population is those answering the QoL questions. Description: Describes 
the proportion of patients with qol scores of low general mental health, general physical 
health, and frequent worry about recurrence.
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Fig. 2. Association between Combined Risk Perception Measure and Frequent Worry†
†Controlling for all covariates. (-) indicates overestimation of risk N: numeric, D: 
descriptive; +: correct (did not overestimate), -: incorrect (did overestimate). Description: 
Describes the odds ratios for the association between the combined numeric/descriptive 
measure on frequent worry.
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Table 1
Demographic and Clinical Characteristics among Patients with Favorable Prognosis 
Breast Cancer (N=927)
Characteristic N or Mean Percent or Minimum – Maximum Weighted Percent or Weighted Mean
SEER Site
Los Angeles County 491 53.0 51.8
Georgia 436 47.0 48.2
Age at survey administration 63.3 31.2 – 82.4 62.8
Race/Ethnicity
Non-Hispanic White 478 51.6 57.7
Non-Hispanic Black 168 18.1 17.7
Hispanic 175 18.9 14.4
Asian 81 8.7 7.5
Missing 25 2.7 2.7
Education
High school or less 273 29.4 27.4
At least some college 645 69.6 71.6
Missing 9 1.0 1.0
Marital Status
Married/partnered 566 61.1 61.4
Not partnered 349 37.7 37.0
Missing 12 1.3 1.5
Employment status
Employed 363 39.2 40.8
Retired 329 35.5 34.7
Unemployed 212 22.9 22.1
Missing 23 2.5 2.3
Breast cancer stage
DCIS (0) 429 46.3 45.0
Low risk invasive 498 53.7 55.0
Comorbidities
None 644 69.5 70.0
One or more 279 30.1 29.7
Missing 4 0.4 0.3
Family history of breast cancer
No 702 75.7 74.3
Yes 225 24.3 25.7
Surgical Treatment
Breast Conserving Surgery 634 68.4 68.3
Unilateral Mastectomy 170 17.0 17.0
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Characteristic N or Mean Percent or Minimum – Maximum Weighted Percent or Weighted Mean
Bilateral Mastectomy 131 14.1 14.4
Missing 4 0.4 0.4
Chemotherapy at time of survey
No 884 95.4 95.9
Yes 33 3.6 3.0
Missing 10 1.1 1.1
Current symptom bother
No 665 71.7 72.8
Yes 243 26.2 24.9
Missing 19 2.1 2.4
Decisional axiety scale 2.5 1 - 5 2.5
Missing 18 1.9 1.9
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Table 2
Multipvariable adjusted logistic regression odds ratios for Poor Mental Health, Poor 
Physical Health and Frequent Worry
Characteristic Odds Ratio, weighted, with 95% confidence interval
Poor Mental Health Poor Physical Health Frequent Worry
Age 0.99 (0.96 - 1.02) 1.01 (0.99 - 1.04) 0.97 (0.95 - 0.99) **
+ 1 year increase
Race/ethnicity:
Non-Hispanic White REF REF REF
Non-Hispanic Black (vs Non-Hispanic White) 0.60 (0.31 - 1.15) 1.78 (1.01 - 3.15) * 1.09 (0.66 - 1.80)
Hispanic (vs Non-Hispanic White) 1.33 (0.59 - 3.00) 1.48 (0.77 - 2.84) 0.75 (0.44 - 1.27)
Asian (vs Non-Hispanic White) 1.22 (0.44 - 3.37) 2.60 (1.14 - 5.92)* 1.09 (0.61 - 1.94)
Education:
Some college or more vs High school or less 1.76 (0.95 - 3.26) 3.18 (1.99 - 5.09)˄ 1.34 (0.88 - 2.06)
Employment status:
Retired vs Employed 2.31 (1.21 - 4.43)* 2.38 (1.32 - 4.31)** 1.32 (0.84 - 2.06)
Unemployed vs Employed 2.49 (1.20 - 5.17)* 2.04 (1.16 - 3.61)* 0.82 (0.50 - 1.34)
Marital Status:
Not married/partnered vs Married/partnered 2.44 (1.41 - 4.20)** 1.18 (0.75 - 1.86) 0.95 (0.66 - 1.35)
Breast cancer stage:
Low risk invasive vs DCIS 0.67 (0.37 - 1.22) 1.06 (0.69 - 1.65) 1.57 (1.10 - 2.25)*
Family history of breast cancer:
Yes vs. No 0.52 (0.28 - 0.97)* 1.12 (0.72 - 1.74) 1.05 (0.69 - 1.61)
Comorbidities:
1 or more vs None 3.42 (2.02 - 5.81)˄ 2.90 (1.89 - 4.44)˄ 1.00 (0.66 - 1.50)
Current symptom bother:
Yes vs No 2.36 (1.44 - 3.87)˄ 6.04 (3.98 - 9.18)˄ 1.30 (0.89 - 1.90)
Decisional anxiety scale:
+1 point increase 2.14 (1.54 - 2.97)˄ 1.14 (0.88 - 1.46) 1.70 (1.37 - 2.11)˄
Descriptive Overestimation:
Yes vs No 2.52 (1.24 - 5.08)* 1.56 (0.84 - 2.91) 3.16 (1.87 - 5.35)˄
Numeric Overestimation:







Controlling for: site, surgical treatment, chemotherapy receipt
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